ORPHA:913
Zollinger-Ellison syndrome
Also known as: Gastrinoma
Publications
8,755
95.8th percentile
Trials
23
Interventional, condition-specific
Researchers
1,020
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare neuroendocrine neoplasm (NEN) characterized by severe peptic disease (ulcers/esophageal disease) caused by hypergastrinemia secondary to a gastrin-secreting NEN (gastrinoma) resulting in increased gastric acid secretion.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019610
- MeSH:D015043
- UMLS:C0043515
- NCIT:C3453
Additional Mondo synonyms (2)
Zollinger Ellison syndrome · Zollinger-Ellison syndrome (disease)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
8,755 matched papers (2,326 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
23 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
8,755
8,755 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
8,755 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2,326 in the last 10 years · high confidence · 95.8th percentile (publications denominator)
Phrase hits: 8,755 · MeSH hits: 0
Who's working on it?
1,020
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Massironi S6 papers · 2025
Division of Gastroenterology Fondazione, IRCCS San Gerardo dei Tintori, Monza, Italia. sara.massironi@libero.it.
Papers in Europe PMC - 02Ito T5 papers · 2025
Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, International University of Health and Welfare, 3-6-45 Momochihama, Sawara-Ku, Fukuoka 814-0001, Japan.
Papers in Europe PMC - 03Jensen RT5 papers · 2025
Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892-1804, USA.
Papers in Europe PMC - 04Cavalcoli F4 papers · 2024
Gastroenterology and Digestive Endoscopy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Papers in Europe PMC - 05Elvevi A4 papers · 2024
Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza 20900, Italy.
Papers in Europe PMC - 06Invernizzi P4 papers · 2023
Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza 20900, Italy.
Papers in Europe PMC - 07Ramos-Alvarez I4 papers · 2025
Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892-1804, USA.
Papers in Europe PMC - 08Bartsch DK3 papers · 2024
Department of Surgery, Philipps-University, 35041 Marburg, Germany.
Papers in Europe PMC - 09Blau JE3 papers · 2025
Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Papers in Europe PMC - 10Kasajima A3 papers · 2026
Department of Pathology, TUM School of Medicine and Health, Technical University Munich, Trogerstr. 18, 81675, Munich, Germany. atsuko.kasajima@tum.de.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
23
interventional trials for this specific condition
23 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 27 July 2026
23 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 94.9th percentile).
high confidence · 94.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
23 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Zollinger-Ellison syndrome" OR "Gastrinoma" OR "Zollinger Ellison syndrome" OR "Zollinger-Ellison syndrome (disease)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Zollinger-Ellison syndrome" OR "Gastrinoma" OR "Zollinger Ellison syndrome" OR "Zollinger-Ellison syndrome (disease)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 23 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T15:54:17.131Z